相关实验视频

Updated: Jan 12, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

作为癌症新型诊断和治疗点的PDE10A:洞察力和挑战

Sahar Ghoflchi^1,2, Ali Nakhaei³, Farzaneh Abbasinezhad-Moud²

¹Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

Frontiers in oncology

|November 3, 2025

概括

二酶10A (PDE10A) 在癌症中具有双重作用,在某些癌症中起作用为瘤基因,并在质母细胞瘤中起作用为瘤抑制剂. 准PDE10A显示了治疗潜力,但需要了解其特定背景的功能.

科学领域:

生物化学生物化学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

基化酶10A (PDE10A) 水解周期性腺单酸盐 (cAMP) 和周期性关单酸盐 (cGMP),调节关键的细胞内信号通路.
PDE10A在中枢神经系统的作用已经确立,有证据表明它具有更广泛的生理和病理相关性,特别是在癌症中.

研究的目的:

探索PDE10A在各种癌症中的情境依赖性作用.
评估PDE10A作为瘤学中的潜在生物标志物和治疗标.

主要方法:

对PDE10A功能,信号通路 (cAMP/PKA,cGMP/PKG) 和它在不同癌症类型中的作用的现有文献的综述.
基于PDE10A的表达和下游途径激活 (Wnt/β-catenin,MAPK/ERK,PI3K/AKT) 的PDE10A瘤原或瘤抑制功能的分析.

主要成果:

在结直肠,卵巢,胃和非小细胞肺癌中,PDE10A充当瘤基因,通过Wnt/β-catenin,MAPK/ERK和PI3K/AKT通路促进扩散.
在临床前模型中,PDE10A的药理抑制证明了抗瘤作用.
在质母细胞瘤中,PDE10A作为瘤抑制剂起作用,其抑制通过PI3K/AKT激活促进瘤进展.

结论:

在瘤学中,PDE10A是一个有希望的,但特定于环境的治疗标和生物标志物.
需要进一步的研究来研究组织特异性表达,循环核酸水平,通路交叉交谈以及有效的治疗策略的PDE10A抑制动态.

关键词:

在PDE10A中,PDE10A是最常见的癌症癌症癌症癌症癌症循环的腺单酸盐.循环诺辛单酸盐的使用基化酶10A的使用情况

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...